Spanish biotechnology firm Araclon has reported positive results from its Phase I clinical trial of ABvac40 to prevent inception of Alzheimer's disease.

ABvac40 is a vaccine immunotherapy designed to act against amyloid beta peptide that is selectively targeting amyloid beta protein 40, using the C-terminal part of the peptide.

The Phase I blinded study included 24 patients with mild to moderate Alzheimer's disease, out of which 18 patients were treated with the ABvac40 and the rest were treated with placebo.

It primarily focused on determining the safety and tolerability of the vaccine, though not the efficacy.

"The results are very promising, although we still have a long way to go."

The results of the study demonstrated the vaccine's safety and tolerability and recorded no significant difference in the adverse effects shown between the placebo group and the other group treated with ABvac40.

It has prompted the company to initiate a Phase II clinical trial.

Araclon Biotech scientific director Manuel Sarasa said: "The results are very promising, although we still have a long way to go.

“We are still at a preliminary stage, and we must be cautious when evaluating the potential success of this project."

The company is also planning to conduct more research focused on an early diagnosis of Alzheimer's disease.

It has already developed ABtest, an early diagnostic test to detect and quantify different Aβ fractions.